.Attributes Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after a typical follow-up of 11 months, patients with metastatic intestinal lumps who got biomarker-matched treatments based upon flowing lump DNA profiling presented a higher clinical advantage than those getting unmatched therapy.